

## FIRST EUROPEAN SALE OF APAS® INDEPENDENCE

*Labor Dr Wisplinghoff in Germany purchases APAS® Instrument for their routine clinical use*

**Adelaide, Australia, 21 October 2019:** Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the first sale of an APAS® Independence instrument in the European Union, to Labor Dr Wisplinghoff in Cologne, Germany.

The purchase of the APAS® Independence by Labor Dr Wisplinghoff was completed following CE Marking, full integration into their laboratory workflow and ongoing collaboration with the Company. Installation of this instrument will support the laboratory with their routine clinical testing.

The transaction was made directly with by LBT's 50% owned joint venture company, Clever Culture Systems who receives this revenue. As a result, LBT will benefit through a reduced funding requirement to the joint venture.

### **Labor Dr Wisplinghoff and APAS® experience**

Labor Dr Wisplinghoff is one of the largest clinical laboratories in Germany and the European union. Their facility is a globally recognised technology leader with over 40 medical specialists covering all the relevant areas of clinical pathology. In April 2018, Labor Dr Wisplinghoff received its first placement of an APAS® Independence as a European centre of excellence for the Company. The laboratory has been a valuable partner for the Company supporting the development of the MRSA analysis module by capturing over 17,000 MRSA culture plate images required for the machine learning process of the analysis module.

Laboratory Director Prof. Hilmar Wisplinghoff, MD is joining LBT Innovations CEO, Brent Barnes to present to investors in Melbourne and Adelaide to share his experience using the technology. They are presenting at a lunch and learn hosted by PAC Partners in Melbourne today. On 24 October 2019, a presentation will be held at the Companies offices in Adelaide.

Prof. Wisplinghoff said:

*"We are very pleased to incorporate the APAS® Independence into our routine clinical workflow, where the instrument will be used daily to automate the reading of our MRSA cultures. We look forward to continuing our collaboration to expand the clinical utility of the instrument."*

Brent Barnes CEO and Managing Director said:

*"This purchase of an APAS® Independence by Labor Dr Wisplinghoff reflects the positive performance experienced by the laboratory over the last 18 months. We are particularly pleased at the benefit this commercial sale to a marquee customer in the EU brings, given their reputation for early adoption of leading-edge technology in our market. With our CE Marking in place we believe we are well placed to target commercial sales to other laboratories in the region."*

– ENDS –

### **About LBT Innovations**

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

**CONTACTS**

<b>LBT Innovations</b>	<b>Investor Enquiries</b>
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>	<b>David Allen / John Granger</b> Hawkesbury Partners Tel: +61 2 9103 9494 E: <a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a>